|
Post by mnkdfann on Aug 8, 2021 9:23:04 GMT -5
I find it interesting that the UTHR press release refers to the "Tyvaso DPI manufacturing facility in Danbury...operated by our partner Mannkind Corporation" It could have said, "owned by our partner Mannkind Corporation" or could it? Update anyone? It could have, but why would it? I think the important thing is who is operating the plant and doing the manufacture. The PR focussed on what is important to UTHR investors. I think if UTHR now owned the facility then that would be relevant to UTHR investors and the PR would have commented on ownership. Otherwise, who owns the plant isn't noteworthy.
|
|
|
Post by mnkdfann on Jul 19, 2021 22:41:25 GMT -5
First, thank you itell, for always finding such interesting MNKD articles. So, here's the thing about this award. Note that there are 1246 total rankings. On 1/1/2021, MNKD only had 241 employees. So, 1005 votes (or, 81% of the total votes) could not have possibly been legitimately from MNKD employees. Just sayin. It says 1246 ratings (not rankings). Probably each participant provided several ratings, i.e. evaluations on different factors. In fact, the blurb on the page says as much: " The overall culture score, 85/100 or A+, incorporates employee ratings based on their feedback on the Perks And Benefits, CEO Rating, Manager and more." Also, some employees may have responded to a long list of rating items, others may have been given a short list of items (like how long and short census forms work). Some may have quit part way through the rating process. To see what I mean, click on the 'Rate This Company' link to see some different rating items. Having said all that, I'm not especially impressed with these awards either. Anyone can claim to work for Mannkind, and do the survey provided.
|
|
|
Post by mnkdfann on Jul 17, 2021 8:50:01 GMT -5
There are those, who of all the thousands of drugs tracked and reported by IMS, the only drug IMS reports false prescription data is apparently Afrezza. Make note— these same Sackler’s founded IMS. I wonder if it may be a little more complicated than that, but Sacklers were certainly involved with IMS. This is an interesting read concerning IMS, it gets into the role of the Sacklers near the end. forward.com/news/359832/the-secret-life-of-the-gay-jewish-immigrant-whose-company-sells-your-medica/I haven't read the book you mentioned, maybe it is talking about the same thing (more or less) regarding IMS.
|
|
|
Post by mnkdfann on Jul 14, 2021 18:54:04 GMT -5
|
|
|
Post by mnkdfann on Jul 10, 2021 13:15:30 GMT -5
That person misinterpreted the MannKind PR to mean that Medicare will now cover Afrezza for all Medicare patients, which is flatly not true. Today another Stocktwits poster claimed that Medicare will cover Afrezza, but only in combination with CGMs, which is also not true. The PR was badly worded, causing much confusion. You raise a good point which had me re-read the PR. I am not sure it is badly worded, maybe carefully worded. I have not talked with Mike in a long time but it seems they are up to something as the PR says Mannkind requested the change. What this does is it gives a reason for CGM vendors to promote afrezza which they never had before. Prior they had reason not to promote afrezza if the PWD was going to get denied in the T1 space let alone trying to do anything with T2s. "Prior to this change, Medicare denials were occurring for patients using CGMs and inhaled insulin as an alternative to injected mealtime insulin," explained Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "MannKind is committed to providing convenience for patients, and believes that patients should have the choice to use any of today's tools to help manage their diabetes." MannKind requested that the Durable Medical Equipment (DME) MACs reconsider the existing language in the LCD: Glucose Monitors (L33822) to include use of inhaled insulin. Previously, the criteria defined patients as taking insulin either with multiple daily injections or an insulin pump. The amended definition now includes a patient that takes insulin with inhalation as an alternative. I don't know what you are thinking of when you wrote 'they are up to something'. I don't think they are being sneaky or that this foretells some big move or change in strategy. The CMS LCD says the same thing about Mannkind requesting the change: "The DME MACs received a reconsideration request on 7/24/2020 from MannKind Corporation, manufacturer of Afrezza inhaled insulin, to change the language in the LCD: Glucose Monitors (L33822) to include use of inhaled insulin. MannKind stated that Medicare denials are occurring for patients using CGMs and inhaled insulin as an alternative to injected mealtime insulin. They requested a change in the criteria for CGM to include ..." I think the CMS is merely indicating that the change came about because the manufacturer made a request, nothing more or less. www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=33822My guess is that Mannkind is simply emphasising the point because from a PR viewpoint it is good to display how proactive they are being (which is still subject to debate, maybe).
|
|
|
Post by mnkdfann on Jul 8, 2021 21:55:50 GMT -5
That data appears to be current as of 2016. Lots has changed. For one, Sanofi bailed. You can see on the site that the number of Afrezza claims was decreasing, and the average patient cost was increasing from 2015 to 2016. I suspect the data is not remotely accurate or relevant for 2020 / 2021.
|
|
|
Post by mnkdfann on Jul 8, 2021 17:59:29 GMT -5
|
|
|
Post by mnkdfann on Jul 8, 2021 0:58:06 GMT -5
Not sure why you do not appear to be thinking there will be any major positives in this for MNKD - Afrezza but I think there will be. More to follow as this moves forward, GL Isn't factual reality better than hopium? While it is a positive, the facts seem to suggest it will amount to weak sauce rather than anything 'major'.
|
|
|
Post by mnkdfann on Jul 6, 2021 8:38:33 GMT -5
I also find it disheartening how the average American will take the first source they hear something from as fact and not take the time to follow it 2, 3 and sometimes 4 levels higher up to find out who is really behind the misinformation. More often than not it usually leads to money or control or control of money and not for what is best for humanity. youtu.be/gAxVaVsM9ng?t=112
|
|
|
Post by mnkdfann on Jul 2, 2021 15:54:12 GMT -5
youtu.be/NBRDmH9TBB0About 2.05 minutes into this video you'll see an Afrezza inhaler in a bag on the table.. Video paid for by Astrazenica..Novo Nordisk and Medtronic..hmm This is a bizarre video. Its sponsored by Medtronic yet they show a Libre. The Afrezza inhaler is on the table why? Are they trying to get their algorithms to be as good as afrezza at mealtime which we know they can't because of absorption or are they mimicking the JDRF effort from 2013 when they used afrezza? And that researcher is at The University of East Anglia, which a public research university in Norwich, England. I figure that video clip is just stock footage / filler, inserted by the people at Nature, without any real input from the researcher or her sponsors.
|
|
|
Post by mnkdfann on Jul 2, 2021 15:35:57 GMT -5
After 3+ years, there are all of 89 subscribers to that podcast, whee!
Of course, that doesn't mean others don't listen to it as well. But safe to say it doesn't attract major listens, which is a shame.
|
|
|
Post by mnkdfann on Jun 30, 2021 23:38:28 GMT -5
Anything New with Mannkind and Brazil? Not exactly new, but sorta newish ... According to the 10K filed on February 25, 2021: investors.mannkindcorp.com/static-files/c200a41e-04e9-4e86-a7d7-c74d7d1e237f Revenue from collaborations and services for the years ended December 31, 2020 and 2019 are as follows (in thousands): Biomm Distribution Agreement: 2020 2019 - 75 Biomm Supply and Distribution Agreement – In May 2017, the Company and Biomm entered into a supply and distribution agreement for the commercialization of Afrezza in Brazil. Under this agreement, Biomm was responsible for pursuing regulatory approvals of Afrezza in Brazil, including from the Agência Nacional de Vigilância Sanitária (“ANVISA”) and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos (“CMED”), both of which have now been received. Biomm commenced product sales in January 2020. In September 2019, the Company delivered its first shipment of Afrezza to Biomm and recorded it as net revenue — commercial product sales for $0.7 million, in advance of the planned launch of the product in Brazil by Biomm. During the second quarter of 2020, the Company sold $0.2 million of product to Biomm. No additional shipments were made in 2020.
|
|
|
Post by mnkdfann on Jun 30, 2021 14:04:11 GMT -5
Three and a half months later: Does this conversion price have anything to do with the share price now? Edit: On March 16, MNKD closed at $3.87. It has most likely has something to do with it. The note buyers want to make sure to make money whether the stock is going down or up. Now that we are getting beyond the conversion price on the notes, they will start to peel off their short exposure in an orderly manner. Or they may have already started to lock in short gains due to substantive news like the acceptance of the application by the FDA or even the recent Medicare announcement. But wouldn't they be better off holding the notes and collecting the interest payments, given they can take advantage of the conversion at $5.21 whenever they like? The way I see it, so long as the SP is above / moving above the conversion price, they are wise to put off conversion as long as they can. They gain nothing (that I can see) by converting early. However, like I said above, without knowing what the 'certain events' mentioned in the notes are, I think we can only really guess whether or not the notes have anything to do with recent SP movement. For instance, it may be they want to convert as one of the 'certain events' occurred / is about to occur, and the conversion price is soon to be adjusted upward. But I can see other possibilities, some bullish, some bearish.
|
|
|
Post by mnkdfann on Jun 30, 2021 12:51:57 GMT -5
Covid maybe? Ask the clinic - info@dgdclinic.com Maybe they read VDex's white papers and just adopted the VDex protocol.Maybe, but I wouldn't bet money on it. There is no mention of Afrezza or an Afrezza study anywhere on its website that I can see, and also no specific mention of inhaled insulin (only injectable and oral medications) under insulin products on its Pharmacy page.
|
|
|
Post by mnkdfann on Jun 30, 2021 9:42:18 GMT -5
WESTLAKE VILLAGE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the "notes") pursuant to the exercise in full of the initial purchasers’ option in connection with MannKind’s previously-announced private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). After giving effect to the additional sale of notes pursuant to the exercise in full of the initial purchasers’ option, MannKind estimates that the total net proceeds from the offering were approximately $222.9 million, after deducting the initial purchasers’ discounts and commissions and estimated offering expenses. The notes are general unsecured obligations of MannKind and will accrue interest at a rate of 2.50% per annum, payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2021. The notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased. Before December 1, 2025, holders will have the right to convert their notes only upon the occurrence of certain events. From and after December 1, 2025, until the close of business on the business day immediately preceding the maturity date, holders will have the right to convert all or any portion of their notes at their election. Upon conversion, MannKind will pay or deliver, as the case may be, cash, shares of MannKind’s common stock or a combination of cash and shares of MannKind’s common stock, at its election. The initial conversion rate is 191.8281 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $5.21 per share of common stock. The initial conversion price represents a premium of approximately 30% over the last reported sale of $4.01 per share of MannKind’s common stock on March 1, 2021. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events. . .. ... Three and a half months later: Does this conversion price have anything to do with the share price now? I'll go out on a limb and guess that without more information, none of us can really know. If I understand the deal correctly, I'll say that if note holders had been converting notes for shares at $5.21, that could be a bullish or bearish sign, depending on their motivation for doing so. Really, it depends on the specifics. E.g. what 'events' are these: holders will have the right to convert their notes only upon the occurrence of certain events
The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events
If you can direct me to a link to a detailed filing listing the specifics, I'll update my guess.
|
|